CNETS NEWS

NET Biomarkers Guideline Published in JAMA Oncology

October 11th, 2024|Comments Off on NET Biomarkers Guideline Published in JAMA Oncology

CNETS is thrilled to announce the publication of a biomarker guideline and patient supplements in JAMA Oncology. Citation: Loree JM, Chan D, Lim J, et al. Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic [...]

Welireg (belzutifan): pCPA Negotiations

September 4th, 2024|Comments Off on Welireg (belzutifan): pCPA Negotiations

The pan-Canadian Pharmaceutical Alliance (pCPA) negotiation process for Welireg (belzutifan) concluded on 2024-08-30. Indication(s): Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) [...]

Expansion of public funding for Lutathera in Ontario to now include pNETs patients

November 10th, 2023|Comments Off on Expansion of public funding for Lutathera in Ontario to now include pNETs patients

Luththera: Funding update for radionuclide therapy for pancreatic neoroendocrine tumours (pNETs). Effective November 7, 2023, Ontario Health will fund the use of Lutathera to treat eligible pancreatic neuroendocrine tumour (pNETs) patients.  This is in addition [...]

Update on Lutathera pCPA Negotiations for pNETs

October 27th, 2023|Comments Off on Update on Lutathera pCPA Negotiations for pNETs

One step closer to access to Lutathera for pNETs patients! The pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with Advanced Accelerator Applications for Lutathera (lutetium 177 dotatate) in pNETs  concluded on 2023-10-17. Negotiation Status: Concluded with [...]

Board Recruitment Announcement

May 21st, 2023|Comments Off on Board Recruitment Announcement

Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the service of a great cause?  Well, [...]

Somatuline Motorized Delivery Device – Press Release

April 9th, 2023|Comments Off on Somatuline Motorized Delivery Device – Press Release

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine [...]

Caring Virtually: A Virtual Care Oncology Patient Study

June 30th, 2022|Comments Off on Caring Virtually: A Virtual Care Oncology Patient Study

I am writing to you as the co-Principal Investigator on CaringVirtually, a virtual care oncology patient study, requesting your support in sharing information about this study with your patient community and anyone else you [...]

CNETS Board Member Awareness

November 4th, 2021|Comments Off on CNETS Board Member Awareness

CNETS Board Member Awareness Patient Education and Fundraising A core function of CNETS is to offer the Canadian neuroendocrine cancer community useful, impactful and informative educational resources [...]